Arcturus FY2025 net loss narrows to $65.8M; revenue falls 46% to $82M; CF program advances

Arcturus Therapeutics Holdings Inc.

Q4 net loss $29.1M ($1.03/shr) vs $30.0M loss prior year; FY net loss $65.8M ($2.40/shr) vs $80.9M.
Revenue Q4 $7.2M, FY $82.0M, down $70.3M YoY due to lower CSL collaboration milestones and supply activity.
Cash $232.8M at Dec 31, 2025; cash runway extended into Q2 2028.
ARCT-032 (CF) third cohort (15 mg, 28 days) safe; 12-week Phase 2 study to start H1 2026.
KOSTAIVE COVID-19 vaccine granted UK MHRA approval in Jan 2026; BARDA pandemic flu vaccine shows durable immune response.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.